Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: Potential implications for plaque stabilization

Journal of Cardiovascular Pharmacology

Volumn 47, Issue 1, 2006, Pages 60-69

  Gómez Hernández, Almudena ^a   Sánchez Galán, Eva ^a   Martín Ventura, José Luis ^a   Vidal, Cristina ^a   Blanco Colio, Luis Miguel ^a   Ortego, Mónica ^a   Vega, Melina ^b   Serrano, Javier ^b   Ortega, Luis ^b   Hernández, Gonzalo ^c   Tunón, José ^a   Egido, Jesús ^a,d  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^c PFIZER INC   (United States)

^d Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Atherosclerosis; Mononuclear cells; Prostaglandin E receptors; Statins

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ACETYLSALICYLIC ACID; ATORVASTATIN; CYCLOOXYGENASE 2; CYTOKINE; DEXAMETHASONE; FARNESYL DIPHOSPHATE; FASUDIL; GELATINASE B; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; MESSENGER RNA; MEVALONIC ACID; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; RHO KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; HEPTANOIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; ISOMERASE; PROSTAGLANDIN E SYNTHASE; PROTEIN SERINE THREONINE KINASE; PYRROLE DERIVATIVE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHO KINASE; RHO-ASSOCIATED KINASE; SIGNAL PEPTIDE;

ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROTIC PLAQUE; CELL CULTURE; CELL LINE; CLINICAL ARTICLE; CULTURE MEDIUM; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; AGED; ATHEROSCLEROSIS; CAROTID ARTERY DISEASE; CHEMISTRY; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

AGED; ATHEROSCLEROSIS; CAROTID ARTERY DISEASES; CELLS, CULTURED; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; INTRAMOLECULAR OXIDOREDUCTASES; MALE; MATRIX METALLOPROTEINASE 1; MEVALONIC ACID; MIDDLE AGED; MONOCYTES; PROTEIN-SERINE-THREONINE KINASES; PYRROLES; RECEPTORS, PROSTAGLANDIN E; RHO GTP-BINDING PROTEINS;

EID: 33646686360     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fjc.0000194252.38683.68     Document Type: Article

References (32)

1. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoids receptors: structures, properties and functions. Physiol Rev. 1999;79:1193-1226.
2. Ballou LR, Botting RM, Goorha S, et al. Nociception in cyclooxygenase isoenzyme-deficient mice. Proc Natl Acad Sci USA. 2000;97:10272-10276.
3. Zhang Y, Guan Y, Schneider A, et al. Characterization of murine vasopressor and vasodepressor prostaglandin E (2) receptors. Hypertension. 2000;35:1129-1134.
4. 2. Am J Physiol. 1999;277:H924-H930.
5. Funk CD, Furci L, FitzGerald GA, et al. Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem. 1993;268:26767-26772.
6. Regan JW, Bailey TJ, Pepperl DJ, et al. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype. Mol Pharmacol. 1994;46:213-220.
7. Kotani M, Tanaka I, Ogawa Y, et al. Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: Multiple second messenger systems and tissue-specific distributions. Mol Pharmacol. 1995;48:869-879.
8. Murakami M, Nakatani Y, Tanioka T, et al. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat. 2002;68-69:383-399.
9. Corcoran ML, Stetler-Stevenson WG, Brown PD, et al. Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J Biol Chem. 1992;267:515-519.
10. Cipollone F, Prontera C, Pini B, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as basis of prostaglandin E2 -dependent plaque instability. Circulation. 2001;104:921-927.
11. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003;59:812-823.
12. Blanco-Colio LM, Tuñón J, Martin-Ventura JL, et al. Anti-inflammatory and immunomodulatory effects of statins. Kidney Int. 2003;63:12-23.
13. Ortego M, Bustos C, Hernandez-Presa MA, et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147:253-261.
14. Hernandez-Presa MA, Martin-Ventura JL, Ortego M, et al. Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells. Atherosclerosis. 2002;160:49-58.
15. Cipollone F, Fazia M, Iezzi A, et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation. 2003;107:1479-1485.
16. Martin-Ventura JL, Blanco-Colio LM, Gomez-Hernandez A, et al. Intensive treatment with atorvastatin reduces blood and plaque inflammation in patients with atherosclerotic lesions in one month. Stroke. 2005;36:1796-1800.
17. Zeng LI, An S, Goetzl EJ. Regulation of expression of MMP-9 in early human T cells of HSB.2 cultured line by the EP-3 subtype of prostaglandin E2 receptor. J Biol Chem. 1996;271:27744-27750.
18. Bustos C, Hernández-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol. 1998;32:2057-2064.
19. Jialal I, Stein D, Balis D, et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation. 2001;103:1933-1935.
20. Sanguigni V, Pignatelli P, Lenti L, et al. Short-term treatment with atorvastatin reduces platelet CD40 ligand and thrombin generation in hypercholesterolemic patients. Circulation. 2005;111:412-419.
21. Simon LS. Role and regulation of cyclooxygenase-2 during inflammation. Am J Med. 1999;106:37S-42S.
22. Murakami M, Naraba H, Tanioka T, et al. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J Biol Chem. 2000;275:32783-32792.
23. Schönbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.
24. Yoneda H, Miura K, Matsushima H, et al. Aspirin inhibits Chlamydia pneumoniae-induced NF-kappa B activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth. J Med Microbiol. 2003;52:409-415.
25. Habara T, Nakatsuka M, Konishi H, et al. The biological effects of antiadhesion agents on activated RAW264.7 macrophages. J Biomed Mater Res. 2002;61:628-633.
26. Mackay DJ, Hall A. Rho GTPases. JBiol Chem. 1998;273:20685-20688.
27. Takemoto M, Liao J. Pleiotropic effects of 3-Hydroxy-3-Methylglutaril coenzyme A reductase. Arterioscler Thromb Vasc Biol. 2001;21:712-719.
28. Schmeck B, Brunsch M, Seybold J, et al. Rho protein inhibition blocks cyclooxygenase-2 expression by proinflammatory mediators in endothelial cells. Inflammation. 2003;27:89-95.
29. Tamma G, Wiesner B, Furkert J, et al. The prostaglandin E2 analogue sulprostone antagonizes vasopressin-induced antidiuresis through activation of Rho. J Cell Sci. 2003;116:3285-3294.
30. Shao J, Sheng H, Inoue H, et al. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J Biol Chem. 2000;275:33951-33956.
31. Shum WW, Le GY, Jones RL, et al. Involvement of Rho-kinase in contraction of guinea-pig aorta induced by prostanoid EP3 receptor agonists. Br J Pharmacol. 2003;139:1449-1461.
32. Wolkowicz PE, Ku DD, Grenett HE, et al. Occupation of the prostaglandin E2-type 1 receptor increases rat atrial contractility via a Y-27632-sensitive pathway. Prostaglandins Other Lipid Mediat. 2002;70:91-105.